Key result
The RESP score poorly discriminated in-hospital survival and death among COVID-19 patients undergoing veno-venous ECMO, with an AUC of 0.61 (95% CI 0.59-0.64).
Why the study?
VV ECMO is used for severe respiratory failure in COVID-19, but the performance of the RESP score in predicting in-hospital survival in these patients needed evaluation.
Does the RESP score accurately predict in-hospital survival in adult COVID-19 patients undergoing VV ECMO?
Cohort (n=1,985)
Yes
Does the RESP score accurately predict in-hospital survival in adult COVID-19 patients undergoing VV ECMO?
Effect estimate: AUC 0.61 (95% CI 0.59-0.64)
The RESP score is a poor predictor of in-hospital survival for COVID-19 patients undergoing VV ECMO, demonstrating poor discrimination compared to its original validation cohort.
The RESP score poorly predicts survival in COVID-19 VV ECMO; leaves open need for disease-specific prognostic tools.
Veno-venous extracorporeal membrane oxygenation (VV ECMO) has been used as a life-supporting modality for patients with severe respiratory failure because of coronavirus disease 2019 (COVID-19). We aim to evaluate the performance of the RESP score in predicting the hospital survival of COVID-19 patients undergoing VV ECMO. We performed retrospective analysis of the extracorporeal life support organization (ELSO) dataset for COVID-19 patients requiring ECMO support to evaluate the performance of RESP score in predicting in hospital survival. All adult (age ≥18) COVID-19 patients receiving VV ECMO for acute respiratory failure enrolled in the ELSO database from March to August 2020 were included in the analysis. A total of 1985 patients from the ELSO registry were identified and analyzed based on pre-ECMO variables. Median RESP score of survivors was 3 (IQR 1-5) compared to 2 (IQR 0-4) in deceased. A logistic model including RESP score variables poorly discriminated survival and death with AUC (area under curve) 0.61 (95% confidence interval: 0.59-0.64). In-hospital survival for COVID-19 patients based on RESP score class from I to V was 69.7%, 59.3%, 45.7%, 42.5%, and 32.3%, respectively. Patients with immunosuppression (relative risk = 0.43) and pre-ECMO cardiac arrest (relative risk = 0.48) had lower survival. RESP score is a poor predictor of survival in COVID-19 patients undergoing ECMO. Compared to the original cohort used for RESP score creation, COVID-19 patients in RESP class I-III had worse survival whereas the patients in RESP class IV-V had better survival.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2022) conducted a cohort in COVID-19 with acute respiratory failure requiring VV ECMO (n=1,985). RESP score was evaluated on In-hospital survival (AUC 0.61, 95% CI 0.59-0.64). The RESP score poorly discriminated in-hospital survival and death among COVID-19 patients undergoing veno-venous ECMO, with an AUC of 0.61 (95% CI 0.59-0.64).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: